| Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area CM Booth, LM Matukas, GA Tomlinson, AR Rachlis, DB Rose, HA Dwosh, ... Jama 289 (21), 2801-2809, 2003 | 1882 | 2003 |
| Monkeypox virus infection in humans across 16 countries—April–June 2022 JP Thornhill, S Barkati, S Walmsley, J Rockstroh, A Antinori, LB Harrison, ... New England Journal of Medicine 387 (8), 679-691, 2022 | 1644 | 2022 |
| Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society–USA panel SM Hammer, JJ Eron, P Reiss, RT Schooley, MA Thompson, S Walmsley, ... Jama 300 (5), 555-570, 2008 | 1292 | 2008 |
| Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America JP Lalezari, K Henry, M O'Hearn, JSG Montaner, PJ Piliero, B Trottier, ... New England Journal of Medicine 348 (22), 2175-2185, 2003 | 1211 | 2003 |
| Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, ... New England Journal of Medicine 369 (19), 1807-1818, 2013 | 1008 | 2013 |
| Lopinavir–ritonavir versus nelfinavir for the initial treatment of HIV infection S Walmsley, B Bernstein, M King, J Arribas, G Beall, P Ruane, M Johnson, ... New England Journal of Medicine 346 (26), 2039-2046, 2002 | 859 | 2002 |
| Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial JM Molina, P Cahn, B Grinsztejn, A Lazzarin, A Mills, M Saag, ... The Lancet 378 (9787), 238-246, 2011 | 520 | 2011 |
| A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis DF Martin, J Sierra-Madero, S Walmsley, RA Wolitz, K Macey, P Georgiou, ... New England Journal of Medicine 346 (15), 1119-1126, 2002 | 487 | 2002 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, H McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 484 | 2021 |
| Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 … CB Hicks, P Cahn, DA Cooper, SL Walmsley, C Katlama, B Clotet, ... The Lancet 368 (9534), 466-475, 2006 | 432 | 2006 |
| Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects JP Allard, E Aghdassi, J Chau, C Tam, CM Kovacs, IE Salit, SL Walmsley Aids 12 (13), 1653-1659, 1998 | 410 | 1998 |
| One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome CM Tansey, M Louie, M Loeb, WL Gold, MP Muller, JA de Jager, ... Archives of internal medicine 167 (12), 1312-1320, 2007 | 405 | 2007 |
| Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 … P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ... The Lancet 393 (10167), 143-155, 2019 | 404 | 2019 |
| A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus … SD Shafran, J Singer, DP Zarowny, P Phillips, I Salit, SL Walmsley, ... New England Journal of Medicine 335 (6), 377-384, 1996 | 401 | 1996 |
| Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study JJ Eron, B Clotet, J Durant, C Katlama, P Kumar, A Lazzarin, ... The Journal of infectious diseases 207 (5), 740-748, 2013 | 364 | 2013 |
| Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection DA Cooper, J Heera, J Heera, J Goodrich, M Tawadrous, M Saag, ... The Journal of infectious diseases 201 (6), 803-813, 2010 | 343 | 2010 |
| Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection C Orkin, K Arasteh, M Górgolas Hernández-Mora, V Pokrovsky, ... New England Journal of Medicine 382 (12), 1124-1135, 2020 | 340 | 2020 |
| Oxidative stress and plasma antioxidant micronutrients in humans with HIV infection JP Allard, E Aghdassi, J Chau, I Salit, S Walmsley The American journal of clinical nutrition 67 (1), 143-147, 1998 | 334 | 1998 |
| Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991 B Demers, AE Simor, H Vellend, PM Schlievert, S Byrne, F Jamieson, ... Clinical infectious diseases 16 (6), 792-800, 1993 | 320 | 1993 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 290 | 2022 |
